SBRA

#1314
Sabra Health Care REIT, Inc. - Common Stock
20.3 4 USD
-0.01%
Market Price
Settore: Immobiliare
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
20.30
20.41
Intervallo Annuale
17.16
22.77
Variazione giornaliera
-1.31%
Variazione Mensile
-3.24%
Variazione di 6 mesi
-1.02%
Variazione Annuale
+11.70%
Chiusura Precedente
20.6 1
Open
20.3 1
Minimo
20.3 0
Massimo
20.4 1
Volume
168
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi Documents

2026

Current report, Q3 FY2026
Sabra Health Care REIT, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Sabra Health Care REIT, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Sabra Health Care REIT, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Sabra Health Care REIT, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Sabra Health Care REIT, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Sabra Health Care REIT, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Sabra Health Care REIT, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Sabra Health Care REIT, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Sabra Health Care REIT, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Sabra Health Care REIT, Inc. current report, Q4 FY2025
8-K

Sabra Health Care REIT, Inc. current report, Q2 FY2026

Full document

Sabra Health Care REIT, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Stockholders held on June 17, 2026. Sabra Health Care REIT, Inc. (SBRA) is a Maryland corporation incorporated to operate as a real estate investment trust. The filing details the outcomes of three specific matters submitted to a vote by security holders.

Key Financial Metrics

This filing is a current report regarding corporate governance and does not contain financial performance data. The text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes and Voting Results

The filing details the final voting tallies for three proposals:

  • Election of Directors: All seven nominees were elected to serve until the 2027 Annual Meeting.
    • Craig A. Barbarosh: 203,295,021 For; 4,352,019 Against.
    • Katie Cusack: 205,669,611 For; 1,508,172 Against.
    • Michael J. Foster: 201,703,451 For; 5,940,779 Against.
    • Lynne S. Katzmann: 202,722,219 For; 4,938,575 Against.
    • Ann Kono: 205,652,052 For; 1,521,149 Against.
    • Jeffrey A. Malehorn: 206,395,107 For; 1,254,574 Against.
    • Richard K. Matros: 201,695,777 For; 5,948,753 Against.
  • Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
    • Result: 226,576,585 For; 1,648,639 Against.
  • Advisory Compensation Vote: Stockholders approved, on an advisory basis, the compensation of named executive officers.
    • Result: 199,568,777 For; 7,867,562 Against.

Guidance, Outlook, and Risks

The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a disclosure of voting results.

Key Facts for Investor Verification

  • Verify the tenure of the newly elected directors, which extends until the 2027 Annual Meeting.
  • Confirm the appointment of PricewaterhouseCoopers LLP as the auditor for the fiscal year ending December 31, 2026.
  • Note the significant number of broker non-votes (20,607,679) recorded for the Election of Directors and Advisory Compensation Vote, indicating shares held by brokers that were not voted on these specific matters.
  • Review the definitive proxy statement filed on April 24, 2026, for details on the executive compensation approved in the advisory vote.

Notizie